Stock Ratings / Health Care / FBLG / forecast

APRE (42) XCUR (35) ENVB (37) ACXP (39) ⌘ Pro Terminal →

FibroBiologics Inc. (FBLG) 12-Month Stock Forecast & Price Target Cone

$0.93 -3.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

FibroBiologics Inc. (FBLG) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $6.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.92 (-0.91%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FBLG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY FBLG SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 36.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.13-14.2% Next Q

Q2 (-2Q)

Grade D$0.97-2.1% Next Q

Q3 (-1Q)

Grade D$0.95-2.1% Next Q

Current

Grade D-$0.93-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FBLG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FBLG currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.31) and Max Pain ($0.98) forces dealer call-delta covering toward $10.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBLG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FBLG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your FBLG Position Size: $10,000

Shares at $0.93: 10752.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.66

$7,097

$-2,903 (-29.0%)

12M Consensus BaseTarget $0.85

$9,140

$-860 (-8.6%)

12M Bull Case BreakoutTarget $10.08

$108,387

+$98,387 (+983.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$9	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBLG)

✓Walkthrough of FBLG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FBLG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.55%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.92H $0.97L $0.90C $0.93VOL 20.7K

RES: $2.88SUP: $0.91SMA50: $1.31SMA200: $2.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FBLG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FBLG Butterfly Map → + Track FBLG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FBLG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FBLG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FBLG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBLG)

Health Care Rank #654 of 1016 ⚔️ APRE vs FBLG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FBLG vs. APRE, XCUR, ENVB, ACXP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, FibroBiologics Inc. (FBLG) ranks #654 by composite RQD confidence (40/100, grade D-) and #924 by equity capitalization ($6.3M). Within this direct 5-issuer industry benchmark cohort, FBLG leads on earnings valuation at N/A trailing P/E, while FBLG leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with FBLG at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FBLG ACTIVE FibroBiologics Inc.	D-	40/100	—	—	-35.0%	-3.99%	$6.3M	Benchmark Subject
APRE Aprea Therapeutics Inc.	D-	42/100	—	—	-35.0%	-8.22%	$6.2M	/apre-vs-fblg →
XCUR Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	/xcur-vs-fblg →
ENVB Enveric Biosciences Inc.	D-	37/100	—	—	-35.0%	-0.68%	$6.5M	/envb-vs-fblg →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-fblg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001958777

In its most recent audited fiscal period (FY2025, filed 2025-12-31), FibroBiologics Inc. (FBLG) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$18.6M, operating cash flow of -$16.4M, and free cash flow of -$16.7M (-37.8% YoY). On the balance sheet, FBLG closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$18.6M	-$16.4M	-$16.7M	$9.6M	—
FY2024 (FY)	2024-12-31	$0	-$11.2M	-$11.9M	-$12.1M	$16.4M	—
FY2023 (FY)	2023-12-31	$0	-$16.5M	-$6.4M	-$6.4M	—	—

3. FBLG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.93 (-3.99% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FBLG ranks #654 in composite RQD confidence.

How does FBLG compare to APRE and XCUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APRE (Aprea Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and XCUR (Exicure Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FBLG?

Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $0 in revenue, -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FBLG trading relative to its 50-day, 200-day, and 52-week technical levels?

FBLG last traded at $0.93 (-3.99% on volume of 18,069 shares), positioning the stock -29.01% below its 50-day simple moving average ($1.31) and -60.92% below its 200-day simple moving average ($2.38). Across its 52-week range of $0.62 to $9.60, FBLG sits at the 3.5% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).

FBLG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is FBLG's 12-month stock price target?

FibroBiologics Inc. (FBLG) carries a 12-month consensus base price target of $0.85 (-8.6% from $0.93), with a bull-case target of $10.08 and a bear-case floor of $0.66.

Is FBLG stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates FBLG D- (Sell — SELL) with an RQD Confidence score of 40/100.

Direct Sub-Reports: FBLG RQD Cockpit FBLG 12M Forecast FBLG Earnings & Move FBLG Dividends & DRIP FBLG Insiders & 13F FBLG Whale Options FBLG Profit Sankey FBLG News & Why